As we close the EASL SLD Summit 2026, thank you to all 440 delegates from 47 countries, our 42 faculty members, our valued industry partners, and our patient organisation attendees.
Over the past days, we explored the latest advances in MASLD, MetALD and ALD, debated the impact of public policy on the SLD environment, and examined emerging therapeutic strategies in an evolving landscape. Most importantly, we strengthened collaboration across disciplines and career stages, with rich discussion at the heart of every session.
CME credits will be awarded to all attendees. Registered delegates can access all sessions on demand via the platform and later on EASL Campus.
Thank you for your energy, insight and commitment to improving care in steatotic liver disease. See you at the SLD Summit 2027 in Berlin, on 11-13 February!
The EASL SLD Summit 2026 aims at updating you on the most recent advances in Steatotic Liver Disease (SLD) including MASLD, MetALD and ALD research, both pre-clinically and clinically and looking into the potential interaction between the 2 most important drivers of SLD. The Summit is a unique opportunity to exchange with both young fellows and established experts in the field in a highly interactive format with a lot of room for discussion.
The Summit will explore whether public policy can reshape the pro-SLD environment, from urban planning to health regulation. A focal topic will this year on ultra processed food and SLD, challenging participants to reconsider the metabolic impact of modern diets.
You will gain insights of optimal patient care in an integrated perspective encompassing the whole spectrum of SLD from the stratification for severity, diagnosis of the subtypes of SLD and management of comorbidities and complications such as HCC in an holistic multidisciplinary approach including an often-overlooked question regarding the strategies to ensure continuity and personalization across life stages.
You will learn about the most recent techniques employed in research, clinical trials and clinical practice, with an understanding of their potential as well as limitations.
Finally, in an evolving landscape of therapies for MASH and MetALD, you will delve into the current and future therapeutic tracks focusing on metabolically directed therapies and liver-directed therapies and discuss whether these therapies should focus on fibrosis improvement or clinical outcomes.
We will conclude the conference by looking towards future horizons, opening a multidisciplinary discussion that builds on fixed points to improve our approach to SLD patient care.
Scope & Topics
- Public health challenges
- Patients care: screening, referral, management of comorbidities
- Transition from pediatric to adult care in patients with SLD
- Diagnosis and NITs in MASLD and MetALD
- Understand the integration of Big Data and AI (Deep Learning, Transformers) in SLD diagnostics and pathology
- Explore single-cell and spatial omics technologies for targeted therapies
- Examine genetic and environmental factors, including alcohol, in SLD progression
- Discuss organoid bioengineering and multiorgan interactions in SLD
- Utilise metabolomics for multiorgan disease modeling (adipose tissue, liver, brain, gut)
- Pharmacological approaches
